Form D · Biotechnology
NGM BIOPHARMACEUTICALS INC
South San Francisco, CA · CIK 0001426332
Offering snapshot reported Mar 25, 2015 · SEC filing
- Reported sold
- $106M Offering amount: $106M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 20, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2015 | Initial | $105,999,996 | No comparison | 1 | SEC filing |
| Feb 24, 2015 | Initial | $20,710,000 | No comparison | 20 | SEC filing |
| May 3, 2013 | Initial | $13,485,015 | No comparison | 14 | SEC filing |
| Nov 7, 2011 | Amendment | $55,389,000 | $16,929,660vs Nov 3, 2011 | 28 | SEC filing |
| Nov 3, 2011 | Amendment | $38,459,340 | $16,929,670vs May 3, 2010 | 28 | SEC filing |
| May 3, 2010 | Amendment | $21,529,670 | $4,500,000vs Apr 5, 2010 | 20 | SEC filing |
| Apr 5, 2010 | Initial | $17,029,670 | No comparison | 19 | SEC filing |
| Dec 22, 2009 | Amendment | $26,550,000 | $2,019,569vs Dec 10, 2009 | 18 | SEC filing |
| Dec 10, 2009 | Amendment | $24,530,431 | $6,913,766vs Nov 13, 2009 | 18 | SEC filing |
| Nov 13, 2009 | Amendment | $17,616,665 | No comparison | 18 | SEC filing |
| Feb 4, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-236650
Sale and issuance of Series E preferred stock and the underlying shares of common stock issuable upon conversion thereof.
Source: Form D, filed Mar 25, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luis Bayol | Executive |
| Jin Long Chen | Director, Executive |
| David V. Goeddel | Director |
| Helen Kim | Executive |
| Mark Leschly | Director |
| Marc Leschly | Director |
| Arthur Levinson | Director |
| William J. Rieflin | Director, Executive |
| David Schnell | Director |
| Peter Svennilson | Director |
| Mc Henry T. Tichenor, Jr. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
630 Gateway Boulevard
South San Francisco, CA, 94080
South San Francisco, CA, 94080